Hormonal therapy of breast cancer with special reference to Masteril therapy.

Abstract

From 1968 to 1972, a trial of a new agent, drostanolone propionate (Masteril), was conducted. This agent was tested against oophorectomy in a group of premenopausal patients, against nandrolone phenylpropionate (Durabolin) in a perimenopausal group, and against ethinyl oestradiol in a postmenopausal group. In the premenopausal group, 44% responded to Masteril and 22% to oophorectomy. In the perimenopausal group, 34,5% responded to Masteril and 39% to Durabolin. In the postmenopausal group, 57% responded to oestrogens and 38,5% to Masteril. The side-effects of Masteril are generally not serious and rarely contra-indicate its use. Masteril has been shown to be a useful and safe agent for all age groups, even though it may appear to be less effective than oestrogens in the postmenopausal patients.

• Authors: M B Bennett, P Helman, P Palmer
• Journal: South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde (S Afr Med J) Vol. 49 Issue 49 Pg. 2036-40 (Nov 15 1975) ISSN: 0256-9574 [Print] South Africa
• PMID: 1242823 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Androgens
• Androstanols
• Ethinyl Estradiol
• Nandrolone

Topics

• Adult
• Aged
• Androgens (adverse effects)
• Androstanols (analogs & derivatives, therapeutic use)
• Breast Neoplasms (drug therapy, therapy)
• Castration
• Ethinyl Estradiol (adverse effects, therapeutic use)
• Female
• Humans
• Menopause
• Middle Aged
• Nandrolone (adverse effects, therapeutic use)